Table 1 Characteristics of patients with bmCRPC on Enzalutamide without PSA-response (decline ≥ 50%)
Variable | all |
|---|---|
Patients [n], (%) | 48 (100) |
Age, median [years] (IQR) | 70.5 (63.0-75.8) |
Bone metastases [n] (%) | 48 (100) |
Lymph node metastases [n] (%) | 38 (79.2) |
Visceral metastases [n] (%) | 13 (27.1) |
Pre chemotherapy [n] (%) | 21 (43.8) |
Post chemotherapy [n] (%) | 27 (56.3) |
Enzalutamide pre Abiraterone [n] (%) | 12 (25) |
Antiresorptive therapy [n] (%) Zoledronic acid [n] (%) Denosumab [n] (%) | 34 (70.8) 17 (35.4) 17 (35.4) |
ECOG (all) [n] (%) 0 1 2 3 | 24 (50.0) 19 (39.6) 4 (8.3) 1 (2.1) |
Gleason-Score ≥ 8 [n] (%) | 23 (47.9) |
Median ALP at baseline [U/l] (IQR) | 155.0 (97.8-304.3) |
Median LDH at baseline [U/l] (IQR) | 274.0 (232.0-352.0) |
Median PSA at baseline [ng/ml] (IQR) | 125.3 (51.2-470.8) |
LDH at baseline > UNL [n] (%) | 39 (81.3) |
Median duration of therapy with Enzalutamide [months] (IQR) | 5.0 (3.0–9.0) |
Median follow up [months] (IQR) | 12.0 (7.0-19.3) |
Patients died during follow up [n] (%) | 41 (85.4) |
Best clinical outcome [n] (%) Complete remission Partial remission Stable disease Progressive disease | 0 (0) 3 (6.3) 30 (62.5) 15 (31.3) |
PD vs. all [n] (%) | 15 (31.3) |
PSA-surge [n] (%) | 10 (20.8) |
LDH-normalization [n] (%) Enzalutamide pre chemotherapy [n] (%) Enzalutamide post chemotherapy [n] (%) | 8 (16.7) 3 (6.3) 5 (10.4) |
ALP rising at 12 weeks [n] (%) Enzalutamide pre chemotherapy [n] (%) Enzalutamide post chemotherapy [n] (%) | 21 (43.8) 8 (16.7) 13 (27.1) |
ALP rising at 12 weeks, without LDH normalization [n] (%) Enzalutamide pre chemotherapy [n] (%) Enzalutamide post chemotherapy [n] (%) | 18 (37.5) 7 (14.6) 11(22.9) |
ALP-bouncing [n] (%) | 3 (6.3) |
Number of following therapies after Enzalutamide [n] (%) 0 1 2 3 4 | 15 (31.3) 15 (31.3) 14 (29.2) 3 (6.3) 1 (2.1) |
Abbreviations: bmCRPC: bone metastatic castration-resistant prostate cancer; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; PSA: prostate specific antigen; UNL: upper normal limit; ECOG: eastern co-operative oncology group; CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease, IQR: interquartile range | |